What's new

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024

Mar 17, 2025 - 14:46
 0
Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024
Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024
Read More

Tags:

Previous Article

BMW: 2025 margins to remain below target

Next Article

Go Outdoors rolls out body cameras to 25 stores

Related Posts

Human medicines European public assessment report (EPAR): Nimenrix, meningococcal groups A, C, W-135 and Y conjugate vaccine, Date of authorisation: 20/04/2012, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 13, 2025  0

European Shortages Monitoring Platform (ESMP): Implemen...

Mar 10, 2025  0

Methylphenidate, prolonged-release tablet 18 mg, 27 mg,...

Feb 10, 2025  0